Key Highlights
•
Children with pediatric-onset multiple sclerosis (POMS) have shorter telomeres, a marker of biological aging, compared to healthy children of the same age. This suggests that the disease itself may accelerate the body’s internal aging process, which could influence long-term health outcomes.
Source →
•
A new international consensus provides standardized guidance for evaluating and managing hypothalamic hamartomas, rare brain lesions that can cause severe seizures. This agreement aims to improve diagnosis and treatment for patients with this complex condition.
Source →
•
A study found distinct patterns of inflammatory markers in the blood of people across the Alzheimer’s disease spectrum, with some markers linked specifically to the presence of amyloid plaques in the brain. This helps separate the general inflammation of aging from the specific inflammation driven by Alzheimer’s pathology, offering potential new targets for treatment.
Source →
•
A large study on childhood chronic uveitis (eye inflammation) found that starting treatment with the drug adalimumab was more effective at achieving remission than starting with methotrexate, especially for inflammation in the back of the eye. This challenges the traditional step-up approach and suggests a more effective first-line treatment for this sight-threatening condition.
Source →
•
Research into the signaling pathway involving SEMA3C and PLXND1 reveals it regulates collagen production in keloid scars through the TGF-β1 pathway. Identifying this new mechanism provides a potential target for developing treatments to prevent or reduce these excessive, painful scars.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
